- Home
- ECVT vs CDTX Comparison
ECVT vs CDTX Comparison
Compare ECVT & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECVT
- CDTX
- Stock Information
- Founded
- ECVT 1935
- CDTX 2012
- Country
- ECVT United States
- CDTX United States
- Employees
- ECVT N/A
- CDTX N/A
- Industry
- ECVT Major Chemicals
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECVT Industrials
- CDTX Health Care
- Exchange
- ECVT Nasdaq
- CDTX Nasdaq
- Market Cap
- ECVT 874.6M
- CDTX 980.1M
- IPO Year
- ECVT 2017
- CDTX 2015
- Fundamental
- Price
- ECVT $8.68
- CDTX $48.89
- Analyst Decision
- ECVT Strong Buy
- CDTX Strong Buy
- Analyst Count
- ECVT 4
- CDTX 11
- Target Price
- ECVT $10.00
- CDTX $52.11
- AVG Volume (30 Days)
- ECVT 1.8M
- CDTX 1.4M
- Earning Date
- ECVT 07-31-2025
- CDTX 08-12-2025
- Dividend Yield
- ECVT N/A
- CDTX N/A
- EPS Growth
- ECVT N/A
- CDTX N/A
- EPS
- ECVT N/A
- CDTX N/A
- Revenue
- ECVT $706,153,000.00
- CDTX $302,000.00
- Revenue This Year
- ECVT $14.91
- CDTX N/A
- Revenue Next Year
- ECVT $4.99
- CDTX N/A
- P/E Ratio
- ECVT N/A
- CDTX N/A
- Revenue Growth
- ECVT 2.23
- CDTX N/A
- 52 Week Low
- ECVT $5.24
- CDTX $10.14
- 52 Week High
- ECVT $9.92
- CDTX $56.83
- Technical
- Relative Strength Index (RSI)
- ECVT 60.25
- CDTX 73.52
- Support Level
- ECVT $8.39
- CDTX $45.59
- Resistance Level
- ECVT $8.90
- CDTX $52.33
- Average True Range (ATR)
- ECVT 0.31
- CDTX 5.13
- MACD
- ECVT 0.02
- CDTX 0.22
- Stochastic Oscillator
- ECVT 85.43
- CDTX 61.27
About ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: (1) Ecoservices and (2) Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.